Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 5Active not recruiting 4Not yet recruiting 2Withdrawn 1Unknown 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Arthritis, Rheumatoid 5Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell 3Leukemia, Myeloid, Acute 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Non-Hodgkin 2Leukemia 2Breast Neoplasms 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Unresectable Pancreatic Carcinoma 1Solid Tumors 1Small Cell Lung Carcinoma 1Sarcoma, Kaposi 1Pancreatic Adenocarcinoma 1Ovarian Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Multi-centric Castleman's Disease 1Melanoma 1Lymphoma 1Lymphohistiocytosis, Hemophagocytic 1Hodgkin Disease 1Hematologic Neoplasms 1Colitis 1Castleman Disease 1Carcinoma, Transitional Cell 1Carcinoma, Neuroendocrine 1

Interventions

Dexamethasone 362Bortezomib 231Lenalidomide 200Cyclophosphamide 174Melphalan 154Calcium Dobesilate 107Peripheral Blood Stem Cell Transplantation 92fludarabine phosphate 84Thalidomide 81Filgrastim 71carfilzomib 68pomalidomide 66Granulocyte Colony-Stimulating Factor 60Mycophenolic Acid 59Busulfan 57daratumumab 54Whole-Body Irradiation 54Tacrolimus 51ixazomib 50Prednisone 50Cyclosporine 49fludarabine 46Antilymphocyte Serum 35Etoposide 30dexamethasone acetate 29Methotrexate 29plerixafor 27Radiotherapy 26Doxorubicin 26dexamethasone 21-phosphate 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Multiple Myeloma × tocilizumab × Clear all
NCT03275103 2026-02-05

Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Genentech, Inc.

Phase 1 Completed
355 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡